Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial.

Autor:	Krouse RS; Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA; Corporal Michael J Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. Electronic address: robert.krouse@pennmedicine.upenn.edu., Anderson GL; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA, USA., Arnold KB; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, Seattle, WA, USA., Thomson CA; Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA., Nfonsam VN; Department of Surgery, University of Arizona, Tucson, AZ, USA; Department of Surgery, Louisiana State University, New Orleans, LA, USA., Al-Kasspooles MF; Department of Surgery, University of Kansas Cancer Center, Kansas City, KS, USA., Walker JL; Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA., Sun V; Division of Nursing Research and Education, City of Hope National Medical Center, Duarte, CA, USA., Alvarez Secord A; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke Cancer Institute, Durham, NC, USA., Han ES; Division of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA., Leon-Takahashi AM; Department of Surgical Oncology, National Cancer Institute, Tlalpan, Mexico City, Mexico., Isla-Ortiz D; Department of Surgical Oncology, National Cancer Institute, Tlalpan, Mexico City, Mexico., Rodgers P; Department of Family Medicine, University of Michigan, Ann Arbor, MI, USA., Hendren S; Department of Family Medicine, University of Michigan, Ann Arbor, MI, USA., Sanchez Salcedo M; Department of Surgery, Instituto Nacional de Enfermedades Neoplásicas, Surquillo, Peru., Laryea JA; Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Graybill WS; Department of Gynecologic Oncology, Medical University of South Carolina, Charleston, SC, USA., Flaherty DC; Department of Surgical Oncology, Valley Health, Winchester, VA, USA., Mogal H; Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA; University of Washington, Seattle, WA, USA., Miner TJ; Department of Surgery, Rhode Island Hospital, Providence, RI, USA., Pimiento JM; Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA., Kitano M; Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, USA., Badgwell B; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA., Whalen G; Department of Surgical Oncology, Umass Memorial Medical Center, Worcester, MA, USA., Lamont JP; Department of Surgery, Baylor University Medical Center, Dallas, TX, USA., Guevara OA; Division of Gastrointestinal Surgery, Instituto Nacional de Cancerologia, Bogota, Colombia., Senthil MS; Department of Surgery, Loma Linda University Health, Loma Linda, CA, USA; University of California-Irvine, Orange, CA, USA., Dewdney SB; Department of Obstetrics and Gynecology Oncology, Rush University Medical Center, Chicago, IL, USA., Silberfein E; Department of Surgery, Baylor College of Medicine, Houston, TX, USA., Wright JD; Division of Gynecologic Oncology, Columbia University Medical Center, New York, NY, USA., Friday B; Department of Hematology/Oncology Essentia Health Cancer Center, Duluth, MN, USA., Fahy B; Department of Surgery, University of New Mexico, Albuquerque, NM, USA., Anantha Sathyanarayana S; Northwell Health Cancer Institute, Lake Success, NY, USA., O'Rourke M; Center for Integrative Oncology and Survivorship, Greenville Health System, Clemson, SC, USA., Bakitas M; School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA., Sloan J; Mayo Clinic Rochester, Rochester, MN, USA., Grant M; Division of Nursing Research and Education, City of Hope National Medical Center, Duarte, CA, USA., Deutsch GB; Northwell Health Cancer Institute, Lake Success, NY, USA., Deneve JL; Department of Surgery, University of Tennessee Health Science Center, Memphis, TN, USA.
Jazyk:	angličtina
Zdroj:	The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2023 Oct; Vol. 8 (10), pp. 908-918. Date of Electronic Publication: 2023 Aug 01.
DOI:	10.1016/S2468-1253(23)00191-7
Abstrakt:	Background: Malignant small bowel obstruction has a poor prognosis and is associated with multiple related symptoms. The optimal treatment approach is often unclear. We aimed to compare surgical versus non-surgical management with the aim to determine the optimal approach for managing malignant bowel obstruction. Methods: S1316 was a pragmatic comparative effectiveness trial done within the National Cancer Trials Network at 30 hospital and cancer research centres in the USA, Mexico, Peru, and Colombia. Participants had an intra-abdominal or retroperitoneal primary cancer confirmed via pathological report and malignant bowel disease; were aged 18 years or older with a Zubrod performance status 0-2 within 1 week before admission; had a surgical indication; and treatment equipoise. Participants were randomly assigned (1:1) to surgical or non-surgical treatment using a dynamic balancing algorithm, balancing on primary tumour type. Patients who declined consent for random assignment were offered a prospective observational patient choice pathway. The primary outcome was the number of days alive and out of the hospital (good days) at 91 days. Analyses were based on intention-to-treat linear, logistic, and Cox regression models combining data from both pathways and adjusting for potential confounders. Treatment complications were assessed in all analysed patients in the study. This completed study is registered with ClinicalTrials.gov, NCT02270450. Findings: From May 11, 2015, to April 27, 2020, 221 patients were enrolled (143 [65%] were female and 78 [35%] were male). There were 199 evaluable participants: 49 in the randomised pathway (24 surgery and 25 non-surgery) and 150 in the patient choice pathway (58 surgery and 92 non-surgery). No difference was seen between surgery and non-surgery for the primary outcome of good days: mean 42·6 days (SD 32·2) in the randomised surgery group, 43·9 days (29·5) in the randomised non-surgery group, 54·8 days (27·0) in the patient choice surgery group, and 52·7 days (30·7) in the patient choice non-surgery group (adjusted mean difference 2·9 additional good days in surgical versus non-surgical treatment [95% CI -5·5 to 11·3]; p=0·50). During their initial hospital stay, six participants died, five due to cancer progression (four patients from the randomised pathway, two in each treatment group, and one from the patient choice pathway, in the surgery group) and one due to malignant bowel obstruction treatment complications (patient choice pathway, non-surgery). The most common grade 3-4 malignant bowel obstruction treatment complication was anaemia (three [6%] patients in the randomised pathway, all in the surgical group, and five [3%] patients in the patient choice pathway, four in the surgical group and one in the non-surgical group). Interpretation: In our study, whether patients received a surgical or non-surgical treatment approach did not influence good days during the first 91 days after registration. These findings should inform treatment decisions for patients hospitalised with malignant bowel obstruction. Funding: Agency for Healthcare Research and Quality and the National Cancer Institute. Translation: For the Spanish translation of the abstract see Supplementary Materials section. Competing Interests: Declaration of interests GLA received payments to Fred Hutch for support for the present manuscript. AAS has grants or contracts from AbbVie, Aravive, AstraZeneca, Boehringer, Ingelheim, Clovis, Eisai, Ellipses, Immunogen, Merck, Oncoquest, Roche/Genentech, SeagenInc, TapImmune, Tesaro/GSK, VBL Therapeutics, and National Cancer Trial Network; has received honoraria for educational presentations or lectures from @Point of Care, Clinical Care Optios, Curio Science, Peerview, Bio ASCEND, RTP, and GOG Foundation; has received honorarium from Myriad; and has received support for attending meetings or travel from GOG, Society of Gynecologic Oncology, and NRG. DCF received support for the present manuscript in the form of payments through S1316 to Valley Health for patient enrolment; received payment or honoraria for lectures from Intuitive for the resident lecture programme; and has stock options in Intuitive. JDW has grants or contracts from Merck; receives royalties or licenses from UptoDate; receives payments for expert testimony from Medicolegal for consulting on gynaecological cancer; is a journal editor for the American College of Obstetricians and Gynecologists. BFa received visiting professor honoraria in April, 2022, at the Ohio State University Department of Surgery, October, 2021, at the University of Nebraska Department of Surgery, and December, 2020, at the University of Tennessee Department of Surgery; and has stock or stock options in Align Tech, Biogen, Bristol Myers Squibb, DexCom, Editas Medicine, Fulgent Genetics, GoodRx Holdings, Guardant Health, Globus Medical, Healthequity, HCA Healthcare, IDEXX Laboratories, Illumina, Intuitive Surgical, Invitae, Masimo, Moderna, Neurocrine Bioscience, Novocure, Quidel, Repligen, Seagen, Shockwave Medical, STAAR Surgical, UnitedHealth Group, Veeva Systems, Teladoc Health, and ResMed. All other authors declare no competing interests. (Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu